Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
Veracyte Inc is a biotechnology business based in the US. Veracyte shares (VCYT) are listed on the NASDAQ and all prices are listed in US Dollars. Veracyte employs 761 staff and has a trailing 12-month revenue of around $268.4 million.
Our top pick for
Beginners
Our top pick for
Free trades
Our top pick for
Social traders
| Latest market close | $16.58 |
|---|---|
| 52-week range | $14.85 - $54.13 |
| 50-day moving average | $22.68 |
| 200-day moving average | $25.39 |
| Wall St. target price | $30.33 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-0.69 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $16.58 from 2022-09-23
| 1 week (2022-09-19) | -11.00% |
|---|---|
| 1 month (2022-08-26) | -22.31% |
| 3 months (2022-06-24) | -27.09% |
| 6 months (2022-03-22) | -41.12% |
| 1 year (2021-09-23) | -68.14% |
|---|---|
| 2 years (2020-09-25) | -46.10% |
| 3 years (2019-09-26) | 24.67 |
| 5 years (2017-09-26) | 92.12% |
| Revenue TTM | $268.4 million |
|---|---|
| Gross profit TTM | $145.1 million |
| Return on assets TTM | -3.73% |
| Return on equity TTM | -4.78% |
| Profit margin | -18.13% |
| Book value | $14.87 |
| Market capitalisation | $1.2 billion |
TTM: trailing 12 months
We're not expecting Veracyte to pay a dividend over the next 12 months.
Over the last 12 months, Veracyte's shares have ranged in value from as little as $14.85 up to $54.13. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Veracyte's is 1.175. This would suggest that Veracyte's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
Veracyte, Inc. operates as a diagnostics company worldwide. The company offers Afirma Genomic Sequencing Classifier and Xpression Atlas, which are used to determine patients with indeterminate results are benign to avoid unnecessary surgery; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; Percepta Genomic Sequencing Classifier and Percepta Nasal Swab Test for lung cancer diagnosis; Envisia Genomic Classifier for diagnosing interstitial lung disease, including idiopathic pulmonary fibrosis; and Immunoscore Colon Cancer test for colon cancer diagnosis. It is also developing Percepta Genomic Atlas to help inform lung cancer treatment decisions; Envisia Classifier, the nCounter analysis system; and LymphMark for lymphoma subtyping test. Veracyte, Inc. has technology licensing and collaboration arrangements with Johnson & Johnson; Acerta Pharma; and CareDx. The company was formerly known as Calderome, Inc.
Looking to invest in tech? Here’s how to buy shares in the major tech companies, known as FAANG stocks.
A simple guide to buying stocks in your favorite European soccer team.
Steps to owning and managing JUVE, with 24-hour and historical pricing before you buy.
Steps to owning and managing ASR, with 24-hour and historical pricing before you buy.
Steps to owning and managing BVB, with 24-hour and historical pricing before you buy.
Everything we know about the Lead Real Estate Co. IPO, plus information on how to buy in.
Everything we know about the Third Harmonic Bio IPO, plus information on how to buy in.
Everything we know about the LINKBANCORP IPO, plus information on how to buy in.
Here are the stocks that benefit from inflation, as well as industries to keep an eye on to reduce the impacts of inflation on your portfolio.
We’ve rounded up stats on some of the most popular wheat stocks, along with information on how these stocks compare and how to invest.
